AtCor Medical Announces New $0.6 Million Pharmaceutical Trial Contract

ITASCA, IL and SYDNEY, AUSTRALIA, Apr 20 (MARKET WIRE)
--
AtCor Medical (ASX: ACG) the developer and marketer of the SphygmoCor(R)
system, which measures central blood pressures and arterial stiffness
noninvasively, today announced that it has signed a new contract to
supply SphygmoCor systems and clinical trial support services to a
leading international pharmaceutical company. This contract is with an
existing client, and has a minimum value of $579,000. The contract brings
the total value of US pharmaceutical trial contracts secured over the
past 11 months to $7.9 million.

Duncan Ross, AtCor Medical CEO, said, "We are again very please to
announce additional business from an existing client. AtCor's strong
customer retention in new clinical trials demonstrates the importance of
noninvasive central blood pressure data in drug development, as well as
the high quality of the services we provide."

Central blood pressure assessment in clinical trials: vital to understand
subject risk and drug effects

"The scientific literature shows how important it is to measure central
blood pressure in clinical trials and in patient care," Ross continued.
"The recently published Anglo Cardiff II study showed that many patients
with controlled brachial blood pressure may have central pressure
equivalent to patients with Stage One Hypertension. Many major independent
studies, such as CAFE and Strong Heart, have shown that elevated central
pressure is a superior predictor of cardiovascular events and that central
blood pressure cannot be determined with brachial blood pressure
measurements. So, to understand existing cardiovascular risk that may be
present in subjects enrolled in trials and the risks and benefits of drugs
in development, central pressures must be measured."

About AtCor Medical

AtCor Medical develops and markets products for the early detection of
cardiovascular risk and management of cardiovascular disease. Its
technology allows researchers and clinical to measure central blood
pressure noninvasively. The company's SphygmoCor system visibly identifies
the effects of reflected blood pressure in the central aortic pressure
wave, effects that cannot be detected with standard blood pressure
monitoring.

More than 1,800 SphygmoCor systems are currently in use worldwide at major
medical and research institutions and in clinical trials with leading
pharmaceutical companies. The company's technology has been featured in
over 400 peer-reviewed studies published in leading medical journals.
AtCor has operations in the United States, Australia, and Europe. For
further information, please visit our web site at www.atcormedical.com.

For further information, please contact:

Duncan Ross
AtCor Medical CEO
T: 630-228-8874

Media:

Larry Watts
AtCor Medical
T: 630-228-8875
l.watts@atcormedical.com

Copyright 2009, Market Wire, All rights reserved.

-0-